Bluebird Bio Opens Gene and Cell Therapy Manufacturing Facility

Published 4-7-2019

Bluebird Bio opened a 125,000-sf gene and cell therapy manufacturing facility in March of 2019 in Durham, N.C. Representing an $80 million investment, the project is bluebird's first wholly owned facility and will support the production of lentiviral vector for clinical and commercial applications. The building, which is now substantially complete and undergoing equipment commissioning, provides multiple manufacturing suites, quality-control testing labs, and warehouse space. The facility was designed to accommodate future expansion which may include the manufacture of commercial drug products.